Quick Answer
LakeShore Biopharma Co., Ltd. reported Operating Income Loss of -$12.02 million for the year ending 2025.
- LakeShore Biopharma Co., Ltd. showed an increase of +97.3% in Operating Income Loss from 2024 to 2025.
- This data is from LakeShore Biopharma Co., Ltd.'s annual report (Form 10-K), filed with the SEC on July 31, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), LakeShore Biopharma Co., Ltd.'s Operating Income Loss has grown by 90.4%.
- Historical annual values: Fiscal year 2025: -$12.02 million | Fiscal year 2024: -$445.83 million | Fiscal year 2023: -$139.38 million | Fiscal year 2022: -$118.96 million | Fiscal year 2021: -$125.85 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: